We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Focused on targeting the source of chronic inflammation, NodThera has completed a $55m Series B round, which was led by Novo Ventures. What makes NodThera an attractive proposition to investors despite the ongoing pandemic?